N/A
Completed N=152
18F-FDG PET Radiomics of Diffuse Large B-cell Lymphoma
Lymphoma, Large B-Cell, Diffuse
Source: ClinicalTrials.gov NCT04317313 ↗
Enrolled (actual)
152
Serious AEs
0.0%
Results posted
Jun 2021
Primary outcomePrimary: Overall Survival — 56; 29 months
Summary
This study aims to investigate the prognostic value of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) radiomics in diffuse large B-cell lymphoma (DLBCL) and its additional value to the International Prognostic Index (IPI).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Overall Survival |
56; 29 | — |
| PRIMARY Progression-free Survival |
52.5; 28 | — |
Eligibility Criteria
Inclusion Criteria
- histopathologically confirmed diffuse large B-cell lymphoma (DLBCL);
- Over 18 years old when diagnosed;
- Have undergone pre-treatment 18F-FDG PET/CT;
- Have been initially treated with the combination of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) or R-EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin).
Exclusion Criteria
- Have primary central nervous system (CNS) lymphoma or second primary cancer;
- Have undergone surgical resection;
- With an incomplete follow-up.
Data sourced from ClinicalTrials.gov (NCT04317313). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.